Efficacy, safety and tolerability of combined low-dose simvastatin- fenofibrate treatment in primary mixed hyperlipidaemia

Clinical Drug Investigation

Volumn 24, Issue 8, 2004, Pages 465-477

  Stefanutti, C ^a   Bucci, A ^a   Di Giacomo, S ^a   Fraone, N ^a   Pace, A ^b   Mareri, M ^a   Musca, A ^a   Mammarella, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; SIMVASTATIN;

ACUTE HEMORRHAGIC PANCREATITIS; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERLIPIDEMIA; LOW DRUG DOSE; MALE; MYOPATHY; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 4344675397     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424080-00005     Document Type: Article

References (40)

1. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary artery disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37-45
2. Cullen P, Schulte H, Assmann G. The Münster Heart Study (PROCAM). Total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 1997; 96: 2128-36
3. Pedersen TR, Olsson AG, Faergeman O, et al. for the Scandinavian Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97 (15): 1453-60
4. Balfour JA, McTavish D, Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990; 40: 260-90
5. Shepherd J. Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13
6. Farnier M, Bonnefous F, Debbas N, et al. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipemia. Arch Intern Med 1994; 154: 441-9
7. Steinmetz A, Schwartz T, Hehnke U, et al. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipoproteinemia. J Cardiovasc Pharmacol 1996; 27: 563-70
8. Ellen RL, Mc Pherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81 (4A): 60B-5B
9. Alaswad K, O'Keefe JH, Moe RM. Combination drug therapy for dyslipidemia. Curr Atheroscler Rep 1999; 1: 44-9
10. Oldemeyer JB, Lund RJ, Koch M, et al. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology 2000; 94 (2): 127-8
11. Kayikcioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999; 83 (7): 1135-7, A9
12. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36 (2): 288-95
13. Matzno S, Tazuya-Murayama K, Tanaka H, et al. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J Pharm Pharmacol 2003; 55 (6): 795-802
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
15. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. JAMA 1999; 282 (21): 2051-7
16. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085-92
17. Ose L, Kastelein JJP, Scott R, et al. for the WSEDP Research Group. Efficacy and six-month safety of simvastatin 80 mg/ day: results from the Worldwide Simvastatin Expanded Dose Program (WSEDP). Nutr Metab Cardiovasc Dis 1998; 8: 135-43
18. Packard CJ. Overview of fenofibrate. Eur Heart J 1998; 19 Suppl. A: A62-5
19. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinemia and cardiovascular disease. Curr Opin Lipidol 1999; 10 (6): 561-74
20. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3 (1): 83-92
21. Devroey D, Velkeniers B, Duquet W, et al. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Acta Cardiol 2003; 58 (3): 179-84
22. Wang CS, McConathy WJ, Kloer HU, et al. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest 1985; 75: 384-90
23. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates down-regulate apolipoprotein C-III expression independently of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995; 95: 705-12
24. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apolipoprotein C-III. J Biol Chem 1995; 270: 13470-5
25. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34 (2): 155-62
26. Gouedard C, Koum-Besson N, Barouki R, et al. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 2003; 63 (4): 945-56
27. Shepherd J. The fibrates in clinical practice: focus on micronised fenofibrate. Atherosclerosis 1994; 110 Suppl.: S55-63
28. Fruchart JC, Brewer HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998; 81: 912-6
29. De la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther 1999; 66 (2): 166-72
30. Fainer M, Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol 2000; 85 (1): 53-7
31. Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fibrate. Arterioscler Thromb Vasc Biol 1997; 17 (9): 793-9
32. Wierzbicki AS, Lumb PJ, Cheung J, et al. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. QJM 1997; 90 (10): 631-4
33. Stein EA, Davidson MH, Dobs AS, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin US Study GROUP. Am J Cardiol 1998; 82 (3): 311-6
34. Bairaktari ET, Tzallas CS, Tsimihodimos VK, et al. Comparison of the efficacy of atorvastatin and micronized fenofibrate in treatment of mixed hyperlipidemia. J Cardiovasc Risk 1999; 6 (2): 113-6
35. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41 (5): 343-70
36. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30 (11): 1280-7
37. Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003; 91 (8): 956-60
38. Gholami K, Tavakoli N, Maleki M, et al. Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia. J Clin Pharm Ther 1998; 23 (3): 213-21
39. McDonald KB, Garber GB, Perreault MM. Pancreatitis associated with simvastatin plus fenofibrate. Ann Pharmacother 2002; 36 (2): 275-9
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6; 360 (9326): 7-22